Key result
Congenital antithrombin III deficiency on warfarin is linked to higher plasma F1+2 levels.
Why the study?
Hereditary antithrombin III deficiency predisposes patients to venous thrombosis and the mechanisms of hypercoagulability and management strategies require further elucidation.
Does warfarin therapy adequately suppress hemostatic system activation in patients with congenital antithrombin III deficiency compared to anticoagulated patients without the disorder?
Observational
Does warfarin therapy adequately suppress hemostatic system activation in patients with congenital antithrombin III deficiency compared to anticoagulated patients without the disorder?
Patients with congenital antithrombin III deficiency on warfarin have higher residual hemostatic system activation than anticoagulated patients without the disorder, suggesting standard anticoagulation may not fully suppress their hypercoagulable state.
Answers are grounded in this paper and cite their sources.
May indicate incomplete suppression on warfarin in antithrombin III deficiency; hypothesis-generating, prospective trials needed before practice change.
Hereditary antithrombin III (ATIII) deficiency predisposes patients to venous thrombosis. The prothrombin fragment F1+2 radioimmunoassay demonstrates that many asymptomatic patients with this disorder not receiving antithrombotic therapy have elevated plasma factor Xa activity. The hemostatic system hyperactivity as measured by this assay could be specifically corrected by rising plasma ATIII levels of several persons into the normal range. This indicates that the prethrombotic state can be defined as an imbalance between the production and inhibition of factor Xa enzymatic activity. The effects of warfarin on factor Xa enzymatic activity in persons with congenital ATIII deficiency have also been evaluated. At equivalent intensities of oral anticoagulation, the mean plasma F1+2 level in patients with ATIII deficiency was significantly elevated as compared with anticoagulated persons without this inherited thrombotic disorder. It is concluded that the effect of warfarin on hemostatic system activation is modulated by the endogenous heparan sulfate-ATIII mechanism. This suggests that the F1+2 radioimmunoassay can be employed to improve the understanding of the hypercoagulable state associated with antithrombin III deficiency as well as to develop more effective treatment strategies to prevent thromboembolic events in patients with this disorder.
No takes yet. Share an insight, caveat, or question.
Bauer et al. (1989) conducted an observational in Congenital antithrombin III deficiency. Congenital antithrombin III deficiency vs. Persons without inherited thrombotic disorder was evaluated on Mean plasma F1+2 level. Patients with congenital antithrombin III deficiency on warfarin had significantly elevated mean plasma F1+2 levels compared to anticoagulated patients without the disorder.
Synapse has enriched 10 related papers. Consider them for comparative context: